Takeda Oncology
Jenifer Siegelman, MD, MPH, serves as an Advisory Board Member at Worcester Polytechnic Institute since 2024. Currently, at Takeda, Jenifer leads a large team in Late Translational Oncology - Clinical Development and has held several senior roles focused on clinical strategies for cell therapies, developing data-driven approaches to improving cancer treatments. Previous positions include serving as an Attending Physician and Quality and Patient Safety Officer at Brigham and Women's Hospital and a Principal Investigator in Lung Cancer at Harvard Medical School. Jenifer founded Siegelman Consultants, specializing in health system software design and digital health applications. Additional experience includes medical director roles at The William W. Backus Hospital and managing partner at Norwich Diagnostic Imaging. Jenifer holds a Master of Public Health from Johns Hopkins Bloomberg School of Public Health and a Doctor of Medicine from the State University of New York Downstate Health Sciences University.
This person is not in any teams
Takeda Oncology
20 followers
In 2008, Takeda Pharmaceutical Company Limited acquired Millennium Pharmaceuticals and the resulting company became exclusively focused on oncology. In 2014, Takeda Oncology was created to become the global headquarters for Takeda’s oncology specialty business unit, in Cambridge, Massachusetts, on the former Millennium Pharmaceuticals site. AtTakeda Oncology they endeavor to deliver novel medicines to patients with cancer worldwide through our commitment to science, breakthrough innovation and passion for improving the lives of patients. This singular focus drives our aspirations to discover, develop and deliver breakthrough oncology therapies. By concentrating the power of leading scientific minds and the vast resources of a global pharmaceutical company, they are finding innovative ways to improve the treatment of cancer.They've built a portfolio of paradigm-changing therapies and a leading oncology pipeline. Though They've made great strides in our fight against cancer, they are determined to do more — to work harder and to reach higher. They continue to seek our aspirations with the same passion, agility and entrepreneurial spirit that has sustained our patient-centric culture and has made us the leaders in oncology that they are today.